- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01960491
FIH Study With CBSO
October 10, 2018 updated by: Carag AG
Prospective Single Center Pilot Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device With Biodegradable Framework in Patients With Clinically Significant Atrial Septum Defect (ASD) or Patent Foramen Ovale (PFO)
The objective of this study is to evaluate the effectiveness and the safety of the intracardiac septal closure device (CBO), as well as the practicability of implantation of this device using the accessories (DS for CBO).
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Frankfurt, Germany
- CardioVaskuläres Centrum
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age greater than 18 years - no upper limit of age
- Body weight > 40 kg
- Patients with an isolated ASD or PFO determined as suitable for closure via a commercially available device
- In ASD patients, echocardiographic evidence of right ventricular overload, and a stretched diameter of the defect up to 25 mm
- In patients with PFO, echocardiographic evidence of right to left shunt, and intraatrial tunnel length up to 4 mm
- Signed informed consent, respectively ability to give written informed consent after being told of the potential benefits and risks of entering the trial
- For female patients of child bearing capacity: Exclusion of pregnancy before start of the study and willingness to use adequate contraceptive methods to prevent pregnancy during the study
Exclusion Criteria:
- ASD/PFO larger than a stretched diameter of 25 mm, or defects unsuitable for percutaneous closure
- Intraatrial tunnel longer than 4 mm
- Multiple or fenestrated ASD, ostium primum or sinus venosus atrial septal defect, coronary sinus defect
- Any significant cardiac valve dysfunction
- Anomalous pulmonary veins
- Defects with inadequate margins, as is consistent with current standards of care, such that the device will not position appropriately so as to avoid interference with other cardiac structure, or that will subject the device to increased risk of embolization post deployment.
- Acquired pathological or congenital deficiencies of the cardiovascular system (any other than ASD; e.g. transposition of vessels, calcification, myocardial infarction, intracardiac thrombi), being clinically significant, respectively interfering in the investigator's opinion with the conduct of study
- Clinically significant dilated cardiomyopathy (paroxysmal or caused by e.g. myocarditis or other reasons)
- Any patient known to have extensive or complex congenital cardiac anomaly which can only be adequately repaired by way of cardiac surgery
- Echocardiographic evidence of thrombus in the left atrium, left atrial appendage, or other cardiac chamber, and in the inferior vena cava.
- Patients who within one month prior to implantation are known to have sepsis or any systemic infection that has not been successfully treated prior to device placement
- Active endocarditis or other infections producing bacteremia.
- Clinically relevant arrhythmia
- Patients whose vasculature, through which access to the defect is gained, is inadequate to accommodate the size of the device, the position controls or the introduction sheath
- Documented history of bleeding, clotting or coagulation disorders, untreated ulcer or any other contraindications to acetylsalicylic acid therapy, unless another anti-platelet agent can be administered for 6 months
- Known hypercoagulable state
- Anamnesis respectively diagnosis of pregnancy, or breastfeeding patients
- Any disorder in the investigator's opinion that could interfere with compliance or safety evaluation as well as any severe concurrent illness that would limit life expectancy (e.g. malignancies)
- Participation in an investigational drug or device trial within 30 days prior to selection (day 0) or current inclusion in any other clinical trial or research project
- Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical trial or will not comply with requirements of the study
- Patients who are kept lawfully in an institution
- Clinical investigations shall be conducted in vulnerable populations only when they cannot be carried out in non-vulnerable populations and shall follow the additional ethics committee procedures where applicable. These clinical investigations shall be designed specifically to address health problems that occur in the vulnerable population, and offer the possibility of direct health-related benefit to the vulnerable population
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Device Closure of Atrial Septal Defect
|
Device Closure of Atrial Septal Defect by "Carag Bioresorbable Septal Occluder"
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Effective closure of defect
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Horst Sievert, Prof. Dr., CardioVaskuläres Centrum Frankfurt, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2014
Primary Completion (Actual)
January 1, 2017
Study Completion (Actual)
June 1, 2018
Study Registration Dates
First Submitted
October 8, 2013
First Submitted That Met QC Criteria
October 9, 2013
First Posted (Estimate)
October 10, 2013
Study Record Updates
Last Update Posted (Actual)
October 11, 2018
Last Update Submitted That Met QC Criteria
October 10, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013.4678
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Septal Defect (ASD)
-
Abbott Medical DevicesRecruitingPFO - Patent Foramen Ovale | VSD - Muscular Ventricular Septal Defect | PIVSD - Post Infarct Muscular Ventricular Septal Defect | ASD - Atrial Septal DefectSpain, Germany, Poland, France, Italy, Netherlands, Switzerland
-
Assiut UniversityWithdrawnASD2(Secundum Atrial Septal Defect)
-
W.L.Gore & AssociatesCompletedSeptal Defect, AtrialUnited States
-
Occlutech International ABCompletedSecundum Atrial Septal Defects
-
Asklepion Pharmaceuticals, LLCCompletedAtrial Septal Defect | Atrioventricular Septal Defect | Ventricular Septal DefectUnited States
-
Ayman khairy MohamedCompletedAtrial Septal Defect, Secundum TypeEgypt
-
Abbott Medical DevicesTerminatedAtrial Septal Defect SecundumUnited States
-
Nobles Medical Technologies II IncEnrolling by invitationForamen Ovale, Patent | Septal Defect, Atrial | Septal Defect, HeartUnited States, Italy
-
HeartStitch.ComUnknownForamen Ovale, Patent | Septal Defect, Atrial | Septal Defect, HeartUnited States
-
W.L.Gore & AssociatesCompleted
Clinical Trials on Device Closure of Atrial Septal Defect
-
Henry Ford Health SystemWithdrawn
-
Carag AGCompleted
-
Lifetech Scientific (Shenzhen) Co., Ltd.Not yet recruitingAtrial Septal DefectItaly, Brazil, Greece
-
Skane University HospitalCompletedCongenital Heart Disease
-
atHeart MedicalActive, not recruitingAtrial Septal Defect | Patent Foramen OvaleGermany
-
Ain Shams UniversityCompletedHeart Defects, CongenitalEgypt
-
Occlutech International ABCompletedSecundum Atrial Septal Defects
-
University Hospital, GhentActive, not recruiting
-
Chinese University of Hong KongRecruiting
-
Fu Wai Hospital, Beijing, ChinaBoston Scientific CorporationRecruiting